A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
A Multicenter, Double-Blind, Randomized Withdrawal Study in Patients With Schizophrenia Receiving Either Iloperidone Long-Acting Injection (LAI) or Placebo Injection
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrials@vandapharma.com202-734-3400
Rogers, Arkansas 72758, United States
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400
202-734-3400